NASDAQ:PODD - Insulet Stock Price, Forecast & News

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet Co. (NASDAQ:PODD) issued its earnings results on Tuesday, November, 5th. The medical instruments supplier reported $0.01 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.03 by $0.02. The medical instruments supplier earned $192.12 million during the quarter, compared to analyst estimates of $179.50 million. Insulet had a net margin of 2.38% and a return on equity of 10.34%. The firm's revenue for the quarter was up 27.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.03 EPS. View Insulet's Earnings History.

Insulet is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Insulet.

Insulet will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

17 equities research analysts have issued 12 month target prices for Insulet's shares. Their forecasts range from $100.00 to $200.00. On average, they anticipate Insulet's stock price to reach $158.82 in the next year. This suggests that the stock has a possible downside of 16.6%. View Analyst Price Targets for Insulet.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 8 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Insulet.

Media coverage about PODD stock has trended somewhat positive on Thursday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Insulet earned a coverage optimism score of 1.6 on InfoTrie's scale. They also gave media stories about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Insulet.

Some companies that are related to Insulet include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR) and Steris (STE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include Alibaba Group (BABA), Netflix (NFLX), NVIDIA (NVDA), DexCom (DXCM), Tandem Diabetes Care (TNDM), Splunk (SPLK), salesforce.com (CRM), Veeva Systems (VEEV), Roku (ROKU) and Adobe (ADBE).

Insulet's stock is owned by many different of institutional and retail investors. Top institutional shareholders include KAMES CAPITAL plc (0.55%), Ambassador Advisors LLC (0.09%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%), Calamos Advisors LLC (0.02%), Tributary Capital Management LLC (0.02%) and First Hawaiian Bank (0.01%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Institutional Ownership Trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including Ambassador Advisors LLC, KAMES CAPITAL plc, Tocqueville Asset Management L.P. and Tributary Capital Management LLC. Company insiders that have sold Insulet company stock in the last year include Aiman Abdel-Malek, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Insider Buying and Selling for Insulet.

PODD stock was acquired by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Zurcher Kantonalbank Zurich Cantonalbank , Polianta Ltd, IFM Investors Pty Ltd, Sciencast Management LP, Alpine Global Management LLC, First Hawaiian Bank and Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PODD stock can currently be purchased for approximately $190.35.

Insulet has a market capitalization of $11.77 billion and generates $563.82 million in revenue each year. The medical instruments supplier earns $3.29 million in net income (profit) each year or $0.05 on an earnings per share basis. Insulet employs 1,169 workers across the globe.View Additional Information About Insulet.

The official website for Insulet is http://www.insulet.com/.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]